Bausch + Lomb (NYSE:BLCO) Price Target Raised to $18.00 at Evercore ISI

Bausch + Lomb (NYSE:BLCO) had its price target boosted by Evercore ISI from $17.00 to $18.00 in a report published on Thursday,Benzinga reports. They currently have an outperform rating on the stock.

Other research analysts have also issued research reports about the company. Zacks Research raised Bausch + Lomb to a “hold” rating in a report on Tuesday, August 12th. The Goldman Sachs Group initiated coverage on Bausch + Lomb in a report on Wednesday, October 1st. They issued a “neutral” rating and a $16.00 target price on the stock. Citigroup reissued a “neutral” rating on shares of Bausch + Lomb in a report on Tuesday, October 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Bausch + Lomb in a report on Wednesday, October 8th. Finally, Wells Fargo & Company boosted their target price on Bausch + Lomb from $15.00 to $16.00 and gave the company an “equal weight” rating in a report on Thursday. Four investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $16.17.

Bausch + Lomb Trading Down 1.8%

BLCO opened at $15.20 on Thursday. The company has a quick ratio of 0.98, a current ratio of 1.55 and a debt-to-equity ratio of 0.76. Bausch + Lomb has a 52 week low of $10.45 and a 52 week high of $20.89. The business’s 50 day moving average is $15.00 and its two-hundred day moving average is $13.56. The firm has a market cap of $5.38 billion, a price-to-earnings ratio of -17.47, a price-to-earnings-growth ratio of 1.68 and a beta of 0.63.

Bausch + Lomb (NYSE:BLCO) last released its quarterly earnings results on Wednesday, October 29th. The company reported $0.18 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.16 by $0.02. Bausch + Lomb had a positive return on equity of 2.42% and a negative net margin of 6.13%.The firm had revenue of $1.28 billion for the quarter, compared to analyst estimates of $1.28 billion. During the same quarter last year, the company posted $0.13 earnings per share. The business’s revenue was up 7.1% on a year-over-year basis. Bausch + Lomb has set its FY 2025 guidance at EPS. On average, research analysts predict that Bausch + Lomb will post 0.74 EPS for the current year.

Institutional Trading of Bausch + Lomb

A number of institutional investors have recently bought and sold shares of BLCO. Tabor Asset Management LP purchased a new stake in Bausch + Lomb during the first quarter worth $338,000. Allianz Asset Management GmbH purchased a new stake in Bausch + Lomb during the first quarter worth $4,712,000. TD Asset Management Inc purchased a new stake in Bausch + Lomb during the first quarter worth $588,000. Clark Estates Inc. NY boosted its position in Bausch + Lomb by 3.7% during the first quarter. Clark Estates Inc. NY now owns 622,000 shares of the company’s stock worth $9,019,000 after purchasing an additional 22,000 shares in the last quarter. Finally, Alberta Investment Management Corp boosted its position in Bausch + Lomb by 8.6% during the first quarter. Alberta Investment Management Corp now owns 3,266,193 shares of the company’s stock worth $47,360,000 after purchasing an additional 258,000 shares in the last quarter. 11.07% of the stock is currently owned by hedge funds and other institutional investors.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.